Misplaced optimism about e-cigarettes for smoking cessation in New Zealand Authors: Alan Blum, Yuhui Yao, Jeremiah Mock Published: 2026 New Zealand deserves recognition for its progress in reducing cigarette smoking and pursuing the goal of becoming a smoke-free nation. In examining New Zealand's recent brief acceleration in the decline of daily smoking among those referred to as adults (i.e., aged 15 years and over) in both the general population and the Māori population, Beaglehole and colleagues conclude that this decline occurred because of what they characterize as a “tobacco harm reduction” effect of the government-endorsed recommendation that adults use e-cigarettes (vapes) for smoking cessation.1 The authors' examination and characterization matters because smoking has contributed to a devastating death toll in the general population and persistent health inequities among Māori, including elevated smoking prevalence and smoking-related disease burden.2 The overall decline in smoking prevalence in New Zealand reflects decades of public health advocacy, policy development, and social change. Yet if New Zealand's recent experience is presented as proof of a net public health benefit from an e-cigarette-centered tobacco harm reduction strategy, then that claim deserves scrutiny. Scientific caution is not merely theoretical. The New Zealand case risks becoming another national tobacco harm reduction model invoked beyond its specific historical and regulatory context. The decline of cigarette smoking in New Zealand did not begin with vaping. Progress took more than six decades after the 1962 Royal College of Physicians report on smoking and health. That slow pace reflected the political and commercial power of the tobacco industry, its suppliers, and other allies, including retailers, advertising agencies, media corporations, agricultural interests, and elected officials. It also reflected fear and foot-dragging within medical societies, public health associations, and universities that too often moved hesitantly—many having accepted tobacco industry research money—while the industry repeated its familiar mantra that “more research is needed.” New Zealand's progress in reducing daily smoking should therefore be understood as cumulative. Grassroots advocacy, led by ASH New Zealand and the National Heart Foundation, for clean indoor air laws, restrictions on tobacco advertising and sports sponsorship, cigarette excise tax increases, plain packaging, graphic warnings, and changing public norms all contributed to declining cigarette consumption. This longer history matters. The authors claim that the brief acceleration in the decline of daily smoking among those ages 15+ was caused by e-cigarettes becoming more widely available and endorsed as a cessation aid. But New Zealand's recent drop in daily smoking should not be attributed too confidently to the rise in e-cigarette use. E-cigarettes are not combustible tobacco products, and no serious critic argues that they cause lung cancer in the same way. On that point, there is substantial agreement. The authors’ principal reduced-harm claim rests on that distinction. But the absence of combustion does not settle the public health question. Long-term effects of e-cigarette use on the cardiovascular system remain uncertain, but we know that nicotine consumption is toxic to the heart and blood vessels.3 Long-term effects of e-cigarette use on the respiratory system, the oral cavity, and the developing brain are also uncertain, but some evidence shows that using e-cigarettes is nearly as risky as smoking cigarettes when it comes to developing asthma, COPD, and periodontal disease.4 Youth and young adult nicotine dependence and the long-term health impacts of e-cigarette use should not be treated as separate, secondary issues, especially given that in New Zealand in the eight years between 2016/17 and 2024/25, the prevalence of daily e-cigarette use among 15–17-year-olds surged sevenfold (from about 2% to about 14%), and among 18–24-year-olds almost eightfold (from about 3% to about 23%), while among 55–64-year-olds the prevalence merely doubled (from about 3% to about 6%).5 The authors note that youth nicotine use is higher than it would have been in the absence of vaping. They also acknowledge that continued monitoring of youth nicotine use remains essential so that reductions in smoking are not offset by unintended long-term harms. Still, the authors’ acknowledgments do not seem to have tempered their strong endorsement of e-cigarettes as a population-level harm reduction strategy. In the UK, which adopted a similar policy to New Zealand in promoting e-cigarettes as a “better alternative” to smoking, among UK youth ages 11–17, the downward trend in the prevalence of ever-smoking reversed recently and increased between 2023 and 2025 from 14% to 21%. These emerging increases should be viewed as an alarming warning sign.6 A further concern is e-cigarette proponents' insufficient distance from the tobacco and nicotine industry's rebranding as “tobacco harm reduction companies” and their “smoke-free future” promotional narratives that appear in prominent international media to target politicians, investors, opinion leaders, and social media influencers. One scientifically unsupported assumption in many e-cigarette-centered arguments is that smokers who switch to using e-cigarettes will not return to smoking cigarettes or become dual users.7,8 Another scientifically unsupported assumption is that because e-cigarettes do not produce combustion, inhaling e-cigarette aerosol must be much less harmful than inhaling cigarette smoke.9 It took several decades in the mid-20th century for non-tobacco-industry-affiliated researchers to generate enough epidemiological and biomedical evidence to show definitively that smoking cigarettes for about 20 or more years can cause lung cancer, emphysema, and heart disease. We do not have 20 years of experience with the use of modern pod-based e-cigarettes and with what the industry calls disposable e-cigarettes to make conclusive statements about the long-term consequences of using this ever-evolving class of products. Thus, the precautionary principle obliges public health and medical professionals to err on the side of caution and not to assume, in the absence of long-term evidence, that using e-cigarettes is less harmful than smoking cigarettes.10 Skepticism is warranted by history. The tobacco industry has repeatedly promoted supposedly safer products, including filtered cigarettes, low-nicotine cigarettes, low-tar cigarettes, and even reduced-carcinogen brands.11,12 Each innovation helped the industry perpetuate the Holy Grail of a safer cigarette while the industry knowingly continued to sell deadly cigarettes. Today's noncombustible nicotine delivery e-cigarettes differ from combustible cigarettes technologically, but they are manufactured and marketed by the same companies that still profit heavily from selling cigarettes. Public health professionals should therefore be cautious about promoting a “tobacco harm reduction” strategy that may also improve the commercial survival and growth of cigarette manufacturers. Polyuse is not accidental. Dual and triple use of nicotine products enable companies to retain consumers across multiple product categories rather than ending nicotine consumption. Even as the tobacco and nicotine companies promote their noncombustible products as evidence of their “transformations,”13, 14, 15 cigarettes remain central to their profits and investors’ expectations. The comparison between combustible cigarettes and e-cigarettes narrows the issue too much. Public health messaging has focused so heavily on the harms of smoking that nicotine addiction itself can become minimized. That is a mistake. There is no established safe level of nicotine consumption from e-cigarettes, and no reliable way to control nicotine uptake when using e-cigarette products. The possibility that users may consume more nicotine through e-cigarettes than through cigarettes should be treated as a serious concern, not an acceptable tradeoff. Public health success should not be defined only as reduced exposure to cigarette smoke while leaving nicotine addiction, youth uptake, polyuse, and uncertainty about long-term negative health effects at the margins. New Zealand's progress in reducing smoking remains important and deserves close attention. But the claim that the recent surge in e-cigarette use, which has been characterized as a “tobacco harm reduction” strategy, led to a brief 3-year decline in daily cigarette smoking is misplaced optimism. The recent, slightly more rapid decline in daily cigarette smoking in New Zealand is more likely the cumulative result of New Zealand's strong implementation of FCTC provisions. New Zealand's FCTC-driven achievements include monitoring the industry, protecting citizens by creating smoke-free environments, offering cessation support, warning the public about the dangers of tobacco, enforcing laws, raising excise taxes, banning tobacco advertising and sponsorship, requiring stronger packaging requirements, and other FCTC provisions. As a whole, these actions contributed to the 3-year decline in daily cigarette smoking among 15+-year-olds.16 New Zealand's recent success reflects decades of public health advocacy and policy implementation that have driven health-affirming sociocultural change. Contributors AB, YY, and JM contributed to the drafting of this manuscript. AB and JM contributed to the editing and final preparation of the manuscript. Declaration of interests The authors declare no conflicts of interest. References